“Afrigen Biologics has earned GMP certification from the South African Health Products Regulatory Authority (SAHPRA), validating Africa’s first fully integrated mRNA manufacturing facility in Cape Town. This milestone strengthens Africa’s ability to produce investigational biological products for clinical trials, reduces reliance on imported vaccines, and enhances pandemic preparedness.”
South Africa has taken a decisive step into the future of biotechnology with Afrigen Biologics achieving GMP certification for its Cape Town-based mRNA manufacturing facility. This milestone is not just a national triumph but a continental breakthrough, symbolizing Africa’s growing capacity to produce advanced vaccines and biologics. GMP certification validates compliance with global safety and quality standards, enabling Afrigen to manufacture investigational biological products for Phase I and II clinical trials.
Why GMP Certification Matters
- Global Standards Compliance: GMP certification ensures adherence to internationally recognized safety and quality benchmarks.
- Clinical Trial Readiness: Afrigen can now manufacture investigational biological products for clinical trials, a critical step toward vaccine innovation.
- Health Sovereignty: By reducing reliance on imports, South Africa strengthens its ability to respond to pandemics and supply vaccines locally.
Lessons from COVID-19
The COVID-19 pandemic exposed Africa’s vulnerability in vaccine access. Wealthy nations secured doses early, while African countries faced delays and shortages. Afrigen’s facility directly addresses this inequity, ensuring that future pandemics do not leave Africa dependent on external suppliers.
Afrigen’s Journey
- 2022–2023: Conceptualization of the mRNA Technology Transfer Programme, co-led by the World Health Organization (WHO) and the Medicines Patent Pool (MPP).
- 2024–2025: Infrastructure development, recruitment of scientists, and establishment of pilot production lines.
- 2026: GMP certification achieved, marking readiness for clinical trial material production.
Strategic Importance
Afrigen’s facility is more than a national achievement—it is a continental asset.
- Pandemic Preparedness: Rapid response capability for emerging infectious diseases.
- Regional Manufacturing Hub: A platform for vaccine production across Africa.
- Innovation Ecosystem: Collaboration between academia, government, and industry to advance biotechnology.
Voices of Leadership
Prof. Petro Terblanche, CEO of Afrigen, emphasized: “This certification is a tribute to the extraordinary commitment of our team. We are ready to support clinical trial production and contribute meaningfully to vaccine development.”
Economic and Social Impact
- Job Creation: The facility has created hundreds of skilled jobs in biotechnology, engineering, and regulatory compliance.
- Capacity Building: Training programs for African scientists ensure knowledge transfer and sustainability.
- Regional Collaboration: Partnerships with universities and research institutions across Africa foster innovation.
Challenges Ahead
- Scaling Production: Moving from pilot-scale to mass production will require significant investment.
- Supply Chain Security: Ensuring uninterrupted access to raw materials remains a challenge.
- Regulatory Harmonization: Aligning standards across African countries is essential for cross-border vaccine distribution.
Global Context
Afrigen’s achievement resonates globally. As nations grapple with health sovereignty, Africa’s ability to produce its own vaccines represents a paradigm shift. It challenges the traditional dependency model and signals Africa’s readiness to contribute to global health innovation.
Conclusion
Afrigen Biologics’ GMP certification is a landmark achievement for South Africa and Africa at large. It represents resilience, innovation, and determination to secure health sovereignty. As the continent prepares for future pandemics, Afrigen’s facility stands as a beacon of hope, ensuring that Africa is no longer a passive recipient of global health solutions but an active contributor to biotechnology innovation.
